Long-term intranasal corticosteroids vs. antihistamines and bone health in post-menopausal women with allergic rhinitis: a retrospective cohort study
Frontiers in Medicine · 10.08.2026 · 13
DOI: 10.3389/fmed.2026.1838641 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Medicine, online erschienen am 10.08.2026. Verfasst von Xiaofei Jia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The Second Hospital of HeBei Medical University, Shijiazhuang, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Intranasal corticosteroids (INCS) are first-line therapy for allergic rhinitis (AR), but their long-term skeletal safety in post-menopausal women—who are inherently vulnerable to bone loss—remains inadequately studied despite low systemic bioavailability.
Methods
This retrospective cohort study included 691 post-menopausal women with persistent AR treated from 2015 to 2023. Participants were categorized into INCS ( n = 198), second-generation antihistamine (sgAH, n = 187), combination therapy ( n = 156), and control ( n = 150) groups. Primary outcomes were changes in bone mineral density (BMD) T -scores and incident osteoporosis. Secondary outcomes included fragility fractures. Multivariable regression analyses were performed with adjustment for confounders, and dose-response relationships were evaluated using defined daily doses.
Results
Over a median follow-up of 4.2 years, INCS users exhibited significantly greater declines in lumbar spine T -scores compared to controls, with similar findings at the femoral neck. sgAH users showed no significant bone loss. Dose-response analysis revealed linear trends for greater bone loss with higher cumulative INCS exposure. Incident osteoporosis occurred in 24.2% of INCS users vs. 11.3% of controls. Fragility fracture rates were highest in the INCS group with adjusted HR 3.85 (95% CI = 1.45–10.24, p = 0.007) vs. controls. sgAH showed no increased fracture risk (HR 1.13, 95% CI = 0.33–3.89). Subgroup analyses identified heightened risk in women aged ≥65 years and those with BMI < 23 kg/m 2 .
Conclusions
Long-term INCS use in post-menopausal women was associated with accelerated bone loss, increased osteoporosis risk, and higher fracture rates in a dose-dependent manner. These findings raise concerns regarding the assumption of complete INCS skeletal safety in post-menopausal women and suggest the need for enhanced bone monitoring in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, The Second Hospital of HeBei Medical University, Shijiazhuang, China.
- Department of Joint Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Zitieren
APA
Jia, X., Liu, L., & Yang, Y. (2026). Long-term intranasal corticosteroids vs. antihistamines and bone health in post-menopausal women with allergic rhinitis: a retrospective cohort study. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1838641
Vancouver
Jia X, Liu L, Yang Y. Long-term intranasal corticosteroids vs. antihistamines and bone health in post-menopausal women with allergic rhinitis: a retrospective cohort study. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1838641
BibTeX
@article{Jia2026,
author = {Jia, Xiaofei and Liu, Lei and Yang, Yanzhong},
title = {Long-term intranasal corticosteroids vs. antihistamines and bone health in post-menopausal women with allergic rhinitis: a retrospective cohort study},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1838641}
}
EUVIMED